Monocytes as Predictors of Cystic Fibrosis-related Bone Disease

NCT04877223 | Unknown

• 1 other identifier: 2020-006-MucOs
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Hypothesis: Circulating monocytes RANK and MCSF-R expression is predictive of Cystic Fibrosis-related Bone Disease. Study design: Single-center comparative cross-sectional study Population: Patients with a CFTR channel mutation causing cystic fibrosis consulting the Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) at Reims University Hospital will be recruited. Healthy controls will be recruited from donors at the Etablissement Français du Sang Grand Est, Reims. Judgment criteria: \- Main judgment criterion: X Expression level of CD115 (MCSF receptor) and CD265 (RANK) evaluated by flow cytometry receptors on the membranes of circulating monocytes. \- Secondary judgment criteria: X Rate of circulating CD115 +, CD265 +, CD115 + / CD265 + monocytes X Number of multinucleated cells with more than 2 nuclei and with an actin ring observed under fluorescence microscopy after osteoclastic differentiation X Surface of dentin resorbed in vitro by osteoclasts during an osteoclastic functionality test on dentin X Serum S1P levels assayed by ELISA technique. Investigation plan: Any eligible patient will be offered to participate in the study during the consultation at the CRCM. If the patient agrees to participate in the study, he/she will be included. Participation in the study will not affect its coverage. Participation will lead to the collection of three tubes of whole blood additional to those used as part of usual care, as well as the collection of demographic data (age, sex, height, weight, body mass index), sports practice, clinical images and interpretation, medical history (diabetes, infectious status, bone metabolism disorders, drug treatments followed, psychiatric disorders). Any subsequent donor from the EFS GE collected under the ALC / PIL / DIR / AJR / FO / 606 agreement and presenting characteristics of age +/- 2 years and identical gender will then be included. Statistical analysis plan: Qualitative variables will be described in terms of number and percentage. The quantitative distribution variables according to the Normal law will be described in the form of mean +/- standard deviation or in the form of boxplots (median, quartiles, deciles) if a distribution not following the Normal law is observed. ANOVA test, non-parametric Wilcoxon signed-rank test or chi² test will be aplied depending on the application conditions. A value of p \<0.05 will be considered statistically significant.

Conditions

Cystic Fibrosis

Keywords

Cystic Fibrosis; Bone disease; Monocytes; RANK; MCSF-R; Osteoclast

Outcome Measures

Primary Outcomes (1)

• Assessment of CD115 and CD265 expression on circulating monocytes

  Flow cytometry

  Immediately after sampling

Secondary Outcomes (4)

• Assessment of CD115+, CD265+ and CD115+/CD265+ cells

  Immediately after sampling

• Count of multinucleated cells with actin ring

  3 weeks after sampling

• Measurement of resorbed dentin surface

  3 weeks after sampling

• Measurement of serum S1P concentration

  Immediately after sampling

Study Arms (1)

CF

Patients with Cystic Fibrosis

Other: No intervention

Interventions

No intervention OTHER

No intervention

CF

Eligibility Criteria

• Age: 20 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Cystic fibrosis patients consulting the CRCM of Reims University Hospital. Healthy controls from Etablissement Français du Sang Grand Est, Reims

You may qualify if:

• Patients between 20 and 65 years (+/- 2 years)
• Patients of the CRCM of Reims University Hospital
• Patients with at least one CF causing mutation in CFTR gene
• Patients agreeing to participate in the study (informed consent form)
• Patients fluent in French
• Patients affiliated with a social security regimen
• Healthy donors between 20 and 65 years (+/- 2 years)
• Healthy donors giving blood at EFS GE, Reims
• Healthy donors agreeing to participate in the study (informed consent form)
• Healthy donors fluent in French
• Healthy donors affiliated with a social security regimen
• Healthy donors whose characteristics agree with the ALC/PIL/DIR/AJR /FO/606 convention between EFS GE, Reims, and Reims Champagne-Ardenne University

You may not qualify if:

• Patient having a medical history that may compromise the protocol (psychiatric, medical or pharmacological disorders such as the use of anti-inflammatory drugs, or any compound that may alter or modify the inflammatory reaction in the week preceding the protocol).
• Pregnant or breastfeeding women
• Patient with eating disorders (anorexia, bulimia, overeating)
• Patient protected by law (guardianship, curatorship, hospitalized without their consent and not protected by law, deprived of liberty)

Sponsors & Collaborators

• Université de Reims Champagne-Ardenne: lead

Study Sites (1)

Université de Reims Champagne-Ardenne

Reims, France

RECRUITING

MeSH Terms

Conditions

Cystic Fibrosis; Bone Diseases

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases; Musculoskeletal Diseases

Study Officials

• Bruno RAVONINJATOVO

  Centre de Ressources et de Compétences de la Mucoviscidose

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Bruno RAVONINJATOVO

CONTACT

03 26 78 38 68; bravoninjatovo@chu-reims.fr

Frédéric VELARD

CONTACT

03 26 91 80 10; frederic.velard@univ-reims.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2021
• First Posted: May 7, 2021
• Study Start: June 1, 2021
• Primary Completion: November 1, 2025
• Study Completion: November 1, 2025
• Last Updated: May 18, 2022

Record last verified: 2022-05

Locations

FR (1)